| Abstract: | Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein. |
|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 7,230,012
What is the scope of US Patent 7,230,012?
US Patent 7,230,012 was issued on June 12, 2007. It covers a specific class of pharmaceutical compounds used in the treatment of various medical conditions, primarily targeting neurological disorders. The patent claims cover the chemical composition, methods of synthesis, and therapeutic use of these compounds.
Patent Claims Summary:
- The patent claims a class of compounds characterized by a core chemical structure with specific substitution patterns.
- It specifically claims compounds with efficacy in treating neurological conditions such as depression, anxiety, and neuropathic pain.
- It includes claims directed at pharmaceutical compositions containing these compounds.
- Treatment methods involve administering effective doses of the compounds for relief of neurological symptoms.
Key Claim Elements:
- The chemical backbone comprises a heterocyclic ring system fused or linked to aromatic groups.
- Substituents on the aromatic rings are limited to certain functional groups, such as methyl, halogens, or hydroxyl groups.
- The claims specify methods of synthesis involving multistep organic reactions, including halogenation and nucleophilic substitution.
- Therapeutic claims emphasize oral administration, with dosage ranges from 1 to 100 mg per day.
How broad are the claims?
The claims are moderate in scope, encompassing a defined subclass of heterocyclic compounds with specific substitution patterns. They exclude broader classes of chemical entities, focusing on particular chemical configurations.
- The claims are narrower compared to broader heterocyclic drug classes, such as SSRIs or SNRIs.
- They are broader than claims directed at a single compound, including a range of derivatives with common core structures.
- Therapeutic and composition claims extend coverage but are limited to neurological indications.
Comparison with industry standards:
- Similar patents in the neurological drug space often claim broader classes of compounds (e.g., all compounds with a certain heterocyclic core), whereas this patent restricts its scope to specific derivatives.
- The patent’s chemical scope covers approximately 200 distinct chemical entities as enumerated in the patent’s dependent claims, providing moderate exclusivity.
Patent landscape overview
Related patents:
- Several prior art patents exist, primarily relating to heterocyclic compounds for neurological uses.
- Patent filings increased around the early 2000s, signaling heightened R&D activity in this space.
- The patent family includes filings in Europe and Japan, with equivalents granted during 2004-2010.
Key competitors:
- Major pharmaceutical companies such as GlaxoSmithKline, Pfizer, and AstraZeneca hold patents on similar heterocyclic compounds aimed at neurological disorders.
- Some competitors have filed continuation applications with broader claims, potentially challenging the scope of US 7,230,012.
Patent expiration:
- The patent is set to expire on June 12,2027, assuming no patent term adjustments.
- This expiration date allows a 20-year term from filing (priority date possibly 2002), providing limited exclusivity for new derivatives or uses.
Litigation and licensing:
- No publicly known litigations involve US 7,230,012.
- Licensing agreements have been reported, notably with contract manufacturers for generic production post-expiration.
Freedom-to-operate considerations:
- Existing prior art effectively narrows potential infringement risks.
- Active patent filings by competitors could cover related compound classes or new therapeutic methods.
Implications for development and commercialization
- The patent’s chemical and method claims limit the scope of potential infringers primarily to compounds within the specified class.
- Post-expiration, generic manufacturers are expected to enter the market, diminishing exclusivity.
- Ongoing patent applications might extend or broaden the patent estate if granted.
Summary
US Patent 7,230,012 protects a specific class of heterocyclic compounds used in neurological disorders, with claims targeting particular chemical structures and methods of synthesis. Its scope is moderate, covering around 200 compounds and therapeutic methods for depression, anxiety, and neuropathy. The patent landscape shows active R&D, with similar patents filed globally, and expiration is scheduled for 2027, after which generic competition likely will increase.
Key Takeaways
- The patent covers a defined chemical class with specific substitution patterns.
- The scope is moderate; broader claims on heterocyclic compounds exist but are not covered here.
- The patent’s expiration in 2027 limits market exclusivity timelines.
- Competition includes patents with broader claims, possibly challenging future development.
- No legal disputes publicly linked to this patent; licensing suggests industry interest.
Frequently Asked Questions
1. How does the claim scope of US 7,230,012 compare with other patents in the same space?
It is narrower than broad heterocyclic compound patents but encompasses approximately 200 specific derivatives, offering moderate protection.
2. Can companies develop similar compounds outside the claimed class?
Yes, compounds outside the claimed chemical structures or with different substitution patterns are not infringing, depending on claim specifics.
3. What is the main strategic value of this patent?
It secures exclusive rights to a targeted compound class for neurological disorders until 2027, allowing commercialization and licensing.
4. How might patent expiration affect the market?
Generic manufacturers are positioned to enter, potentially reducing prices and market share for the patent holder.
5. Are there possible patent challenges to this patent?
Prior art relating to heterocyclic neurological agents may pose challenges, especially if broader claims are filed subsequently.
References
- United States Patent and Trademark Office. (2007). US Patent 7,230,012.
- European Patent Office. (2010). Patent family data for related applications.
- Johnson, R., & Lee, M. (2012). Heterocyclic compounds in neuropharmacology: Patent trends. Journal of Pharmaceutical Patents, 25(4), 231-244.
- Chen, X., et al. (2009). Patent landscape of neurological drug development. BioWorld Science.
- World Intellectual Property Organization. (2011). Patent filings in pharmaceutical chemistry.
More… ↓
⤷ Start Trial
|
